摘要
AIM:To investigate the roles of H pylori vaccine with chitosan as adjuvant in the immunological therapy of H pylori infection. METHODS:Female BALB/c mice infected H pylori were randomly divided into group A,B, C,D and E,which were treated with phosphate buffered saline （PBS）,H pylori antigen,H pylori- antigen plus chitosan solution,H pylori antigen plus chitosan particles,and H pylori antigen plus cholera toxin （CT）,respectively.The vaccine was orally given once a week for 4 weeks.At the 4th week after the last immunization,these mice were killed and gastric mucosa were embedded in paraffin,then assayed with Giemsa and HE staining.At the same time,quantitative H pylori culture was performed,and enzyme-linked im- munosorbnent assay （ELISA） was used to detect anti-H pylori IgA in saliva and gastric mucosa and anti-H pylori IgG in serum. RESULTS:In the groups with chitosan as adju- vant,the eradication of H pylori was achieved in 58.33% mice,which was in accordance with that in the group with CT as adjuvant （45.45%）,and the colonization density of H pylori in the groups with chitosan as adjuvant was significantly lower than that in the other groups （F=24.166,P<0.05-0.001）.The degrees of acute inflammation in gastric mucosal were significantly lower in mice with adjuvant than those in group A and B （H =21.873,P<0.05-0.001）;the degrees of chronic inflammation in gastric mucosal were signifi- cantly lower in the groups with adjuvant chitosan than those in the other groups （H=20.213,P<0.05-0.001）.The levels of specific anti-H pylori IgA in gastric mucosa （60.18±19.87,63.01±20.92, 61.16±22.25） and saliva （3.28±1.38,2.81±1.56, 3.03±1.52）,and specific anti-H pylori IgG （12.73±3.95,12.06±4.84,11.83±4.31） in sera in the groups with adjuvant were significantly higher than those in group A （saliva:1.19±0.63,gastric mucosa:15.56±6.24,serum:6.56±3.50） and group B （saliva:1.32±0.30,gastric mucosa:27.25±6.56,serum:7.86±4.02） （P<0.05-0.001）. CONCLUSION:H pylori vaccine with chitosan as adjuvant can eradicate or significantly reduce H pylori colonization in the gastric mucosa of mice and induce local specific humoral immune response in gastric mucosa successfully.
AIM： To investigate the roles of H pylori vaccine with chitosan as adjuvant in the immunological therapy of H pylori infection.
METHODS： Female BALB/c mice infected H pylori were randomly divided into group A, B, C, D and E, which were treated with phosphate buffered saline （PBS）, H pylori antigen, H pyloriantigen plus chitosan solution, H pylori antigen plus chitosan particles, and H pylori antigen plus cholera toxin （CT）, respectively. The vaccine was orally given once a week for 4 weeks. At the 4^th week after the last immunization, these mice were killed and gastric mucosa were embedded in paraffin, then assayed with Giemsa and HE staining. At the same time, quantitative H pylori culture was performed, and enzyme-linked immunosorbnent assay （ELISA） was used to detect anti-H pylori IgA in saliva and gastric mucosa and anti-H pylori IgG in serum.
RESULTS： In the groups with chitosan as adjuvant, the eradication of H pylori was achieved in 58.33% mice, which was in accordance with that in the group with CT as adjuvant （45.45%）, and the colonization density of H pylori in the groups with chitosan as adjuvant was significantly lower than that in the other groups （F = 24.166, P 〈 0.05-0.001）. The degrees of acute inflammation in gastric mucosal were significantly lower in mice with adjuvant than those in group A and B （H = 21.873, P 〈 0.05-0.001）; the degrees of chronic inflammation in gastric mucosal were significantly lower in the groups with adjuvant chitosan than those in the other groups （H = 20.213, P 〈 0.05-0.001）. The levels of specific anti-H pylori IgA in gastric mucosa （60.18 ± 19.87, 63.01 ± 20.92, 61.16± 22.25） and saliva （3.28 ± 1.38, 2.81 ± 1.56, 3.03 ± 1.52）, and specific anti-H py/or/IgG （12.73 ± 3.95, 12.06 ± 4.84, 11.83 ± 4.31） in sera in the groups with adjuvant were significantly higher than those in group A （saliva：1.19 ± 0.63, gastric mucosa： 15.56 ± 6.24, serum： 6.56 ± 3.50） and group B （saliva： 1.32 ± 0.30, gastric mucosa： 27.25 ± 6.56, serum： 7.86 ± 4.02） （P 〈 0.05-0.001）.
CONCLUSION： H pylori vaccine with chitosan as adjuvant can eradicate or significantly reduce H pylori colonization in the gastric mucosa of mice and induce local specific humoral immune response in gastric mucosa successfully.
出处
《世界华人消化杂志》
CAS
北大核心
2007年第6期561-567,共7页
World Chinese Journal of Digestology
基金
国家自然科学基金
No.30460052
江西省学科带头培养项目
No.K010501~~
关键词
幽门螺杆菌
壳聚糖
治疗性疫苗
佐剂
Helicobacter pylori
Chitosan
Therapeutic vaccine
Adjuvant
